Journal of Alzheimer's disease reports最新文献

{"title":"Association between the coronavirus disease pandemic and antipsychotic drug prescriptions among patients with dementia.","authors":"Kyungduk Hurh, Hyunkyu Kim, Eun-Cheol Park","doi":"10.1177/25424823261435562","DOIUrl":"10.1177/25424823261435562","url":null,"abstract":"<p><strong>Background: </strong>Antipsychotics are frequently prescribed off-label to manage behavioral and psychological symptoms of dementia but pose safety risks in older adults, including a 1.5-2.0-fold increased risk of mortality. The coronavirus disease (COVID-19) pandemic disrupted dementia care, increasing reliance on pharmacologic treatments.</p><p><strong>Objective: </strong>This study aimed to evaluate whether the COVID-19 pandemic was associated with changes in the prevalence of antipsychotic prescribing among patients with dementia.</p><p><strong>Methods: </strong>Using the Korean National Health Insurance Database, this study analyzed a random 50% sample of eligible individuals aged ≥60 years diagnosed with dementia between 2016 and 2021 (n = 876,158; 9.8 million person-observations). Outcomes included the likelihood, duration, and number of antipsychotic prescriptions issued, characterizing pharmacologic management of dementia. Interrupted time series analysis assessed associations between the pandemic and relative changes in these outcomes, adjusting for demographic factors, comorbid burden, and seasonality.</p><p><strong>Results: </strong>After the pandemic onset, there were relative slope increases per quarter of 1.5%, 3.2%, and 0.4% in the likelihood, duration, and number of prescriptions, respectively (all p < 0.001; pre-pandemic levels: 0.172 patients prescribed, 12.97 days, and 18.10 prescriptions per person-quarter). Antipsychotic prescriptions decreased by 1.6% (p < 0.001) during the first quarter after the outbreak but subsequently showed a progressive increase, reflecting prolonged care disruption after initial access barriers.</p><p><strong>Conclusions: </strong>The COVID-19 pandemic was associated with increased antipsychotic prescribing among patients with dementia. To mitigate similar effects in future public health crises, governments and healthcare providers should strengthen mental health support, non-pharmacological interventions, telehealth continuity, and tailored prescribing guidelines.</p>","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"10 ","pages":"25424823261435562"},"PeriodicalIF":2.8,"publicationDate":"2026-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13039037/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147610827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microbiome alterations in Alzheimer's disease: A systematic review of current evidence and global perspectives.","authors":"Tolutope Adebimpe Oso, Olalekan John Okesanya, Uthman Okikiola Adebayo, Khalifat Boluwatife Obadeyi, Oluwatobi Babajide Ayelaagbe, Olusola Adetunji Talabi, Pelumi Daniel Adewole, Chioma Ogochukwu Anorue, Mohamed Mustaf Ahmed, Oluwatimileyin Titilayo Talabi, Jerico Bautista Ogaya, Don Eliseo Lucero-Prisno","doi":"10.1177/25424823261436287","DOIUrl":"10.1177/25424823261436287","url":null,"abstract":"<p><strong>Background: </strong>Growing evidence implicates the gut-brain axis in Alzheimer's disease (AD), with gut microbiome dysbiosis proposed to modulate neuroinflammation, amyloid pathology, and cognitive decline.</p><p><strong>Objective: </strong>To systematically synthesize human studies (2021-2025) profiling gut microbiomes in AD; identify consistent taxonomic and functional signatures; map geographic study distribution; and highlight translational gaps.</p><p><strong>Methods: </strong>A PRISMA-compliant systematic review of human studies using 16S rRNA, metagenomics, metatranscriptomics, or fecal microbiota transplantation (FMT)/probiotic designs was conducted. Two reviewers screened studies and assessed quality using Joanna Briggs Institute tools. Owing to heterogeneity, findings were narratively synthesized across microbiome diversity, taxonomy, function, metabolism, oral-brain links, causality, interventions, and predictive analyses.</p><p><strong>Results: </strong>Thirty-seven studies, mainly from Asia with some from Europe, North America, and Africa, revealed consistent gut dysbiosis in AD. Findings show reduced alpha-diversity, loss of short-chain fatty acid-producing bacteria (e.g., <i>Faecalibacterium prausnitzii</i>, <i>Bifidobacterium</i>), and enrichment of pro-inflammatory taxa (<i>Escherichia/Shigella</i>, <i>Proteobacteria</i>). Functional analyses indicate reduced butyrate synthesis, disrupted lipid and tryptophan-kynurenine metabolism, and links with apolipoprotein epsilon (ε4) gene and cognition. Limited causal evidence arises from Mendelian randomization and small FMT trials, with randomized, longitudinal confirmation still needed.</p><p><strong>Conclusions: </strong>Current evidence suggests a biologically plausible association between gut microbiota and AD pathogenesis, positioning microbiome-derived biomarkers and interventions as promising but still exploratory avenues. Harmonized, longitudinal, multi-omic, and geographically inclusive studies are urgently needed to clarify causal mechanisms and translate these correlational findings into validated diagnostics and therapeutics.</p>","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"10 ","pages":"25424823261436287"},"PeriodicalIF":2.8,"publicationDate":"2026-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13039051/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147610583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of anticoagulation on cognitive decline and clinical outcomes in patients with atrial fibrillation and dementia: A retrospective cohort study.","authors":"Yun Du, Weng-Chio Tam, Man-Fong Chu, Sio-Mui Wong, Kuok-Wun Lam, Tat-Kuong Tong, Mei-Hong Wong, Chon-Hou Chan, Weng-Hong Pun, Mario Evora, U-Po Lam, Iek-Long Lo","doi":"10.1177/25424823261433532","DOIUrl":"10.1177/25424823261433532","url":null,"abstract":"<p><strong>Background: </strong>Atrial fibrillation (AF) and dementia frequently coexist in older adults, yet the impact of anticoagulation on cognitive and clinical outcomes in this population remains uncertain.</p><p><strong>Objective: </strong>To evaluate the effects of anticoagulation on cognitive and clinical outcomes in patients with AF and dementia.</p><p><strong>Methods: </strong>This retrospective cohort study included 291 patients aged ≥65 years with AF and dementia, treated at a tertiary center between January 2020 and December 2024. Patients were grouped by anticoagulation status. Cognitive, functional outcomes (Mini-Mental State Examination [MMSE], Activities of Daily Living [ADL], Clinical Dementia Rating-Sum of Boxes [CDR-SB]) and clinical endpoints (all-cause mortality, hospitalization, major adverse cardiovascular events, and bleeding) were assessed over a median 28-month follow-up.</p><p><strong>Results: </strong>Anticoagulated patients were younger (82.8 versus 85.1 years, <i>p</i> = 0.01). Anticoagulation was associated with slower cognitive/functional decline, with medium effect sizes, ΔMMSE mean difference: 2.0 points (95% CI: -3.5 to -0.4; <i>p</i> = 0.048), ΔADL mean difference: 10.9 points (95% CI: -19.6 to -2.3; <i>p</i> = 0.02), ΔCDR-SB mean difference: -1.4 points (95% CI: 0.4 to 2.4; <i>p</i> < 0.01). In multivariable Cox models, anticoagulation reduced hospitalization risk (HR 0.60; 95% CI: 0.43-0.84; <i>p</i> < 0.01) and all-cause mortality (HR 0.59; 95% CI: 0.40-0.88; <i>p</i> = 0.01). Benefits were most pronounced in very mild dementia and Alzheimer's disease.</p><p><strong>Conclusions: </strong>In this retrospective, confounder-adjusted study, anticoagulation was associated with slower cognitive/functional decline and lower hospitalization/mortality risk in AF and dementia patients. The findings warrant prospective research to investigate whether anticoagulation has disease-modifying effects in early-stage dementia.</p>","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"10 ","pages":"25424823261433532"},"PeriodicalIF":2.8,"publicationDate":"2026-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13039085/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147610530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to Unraveling the impact of common medications on biomarker patterns in Alzheimer's disease and mild cognitive impairment.","authors":"","doi":"10.1177/25424823261433792","DOIUrl":"10.1177/25424823261433792","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1177/25424823251387281.].</p>","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"10 ","pages":"25424823261433792"},"PeriodicalIF":2.8,"publicationDate":"2026-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13039076/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147610582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estimates of current capacity for diagnosing and implementation of new treatment Alzheimer's disease in Slovenia.","authors":"Eva Zupanic, Gašper Stegnar, Martin Rakuša, Polona Rus Prelog, Igor Švab, Milica Gregoric Kramberger","doi":"10.1177/25424823261424524","DOIUrl":"10.1177/25424823261424524","url":null,"abstract":"<p><strong>Background: </strong>The limited efficacy of current symptomatic treatments for Alzheimer's disease (AD) leads many patients to forgo medical help. However, new disease-modifying treatments (DMTs), such as donanemab and lecanemab, show potential to change this.</p><p><strong>Objective: </strong>To model the impact of these treatments on Slovenia's healthcare system by analyzing patient flow under both current and enhanced capacities, assuming DMT availability.</p><p><strong>Methods: </strong>The study estimates 76,923 potential DMT candidates aged 65 years and older with mild cognitive impairment or mild AD. Using data from Slovenia's three specialized centers for cognitive disorders, a Markov model simulated five five-year scenarios: baseline, real-life, real-life with capacity enhancement, biomarker integration, and biomarker integration with capacity enhancement.</p><p><strong>Results: </strong>Waiting times for specialist evaluation would increase from the current 3-12 months to 1.8 years. The primary bottleneck is lumbar puncture with cerebrospinal fluid (CSF) analysis, during which 64% of patients would become ineligible for DMT. The shortest waiting time to receive DMT occurs in the biomarker integration with capacity enhancement scenario, at 4 years, reducing ineligibility to 7%.</p><p><strong>Conclusions: </strong>Current specialized outpatient facilities are limited, causing significant bottlenecks, especially in CSF analysis. Severe waiting times under current capacities mean many patients would progress to moderate or severe dementia or die before receiving treatment. Plasma biomarkers offer a promising triage approach to guide patients toward lumbar puncture or other confirmatory diagnostics, potentially easing this critical bottleneck. Substantial infrastructure and workforce improvements are essential to ensure timely and equitable access to DMTs in Slovenia.</p>","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"10 ","pages":"25424823261424524"},"PeriodicalIF":2.8,"publicationDate":"2026-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13039032/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147610532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Cheung Glutamatergic Regimen as a candidate for primary and secondary prevention of Alzheimer's disease onset.","authors":"Ngo Cheung","doi":"10.1177/25424823261433953","DOIUrl":"10.1177/25424823261433953","url":null,"abstract":"<p><p>Ketamine's ability to lift mood and spur new synapse growth has put glutamate biology at the center of modern neurotherapeutics. Yet the drug's intravenous route, monitoring requirements, and dissociative effects make it a poor candidate for long-term prevention of Alzheimer's disease (AD). This hypothesis article proposes a low-cost oral glutamatergic regimen that targets early synaptic and glutamatergic dysfunction in AD pathogenesis. Here we advance a testable hypothesis: an all-oral \"synaptogenic stack\" could mimic ketamine's downstream benefits-namely, the rise in brain-derived neurotrophic factor and the activation of mechanistic target of rapamycin (mTOR)-while avoiding its toxicities. The stack combines three inexpensive agents that have decades of human use. First, dextromethorphan, kept in circulation with a small dose of a CYP2D6 inhibitor, provides gentle NMDA antagonism. Second, piracetam acts as a positive modulator of AMPA receptors, boosting fast excitatory transmission. Third, oral L-glutamine replenishes presynaptic glutamate stores and buffers against excitotoxic spill-over. Working in concert, these drugs should reduce extrasynaptic NMDA stress, enhance AMPA throughput, and preserve dendritic spine density in the aging brain. If this mechanism proves sound, the regimen offers a low-cost, scalable way to delay the clinical onset of AD, particularly in people who already show prodromal biomarkers or genetic risk. Prospective trials are needed to evaluate safety, target engagement, and long-term cognitive outcomes.</p>","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"10 ","pages":"25424823261433953"},"PeriodicalIF":2.8,"publicationDate":"2026-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13039054/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147610868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Qualitative insights into participant and care partner perspectives on research-based Alzheimer's disease biomarker testing and disclosure.","authors":"Annalise Rahman-Filipiak, Mary Lesniak, Alicia Burgei, Shima Sadaghiyani, J Scott Roberts, Peter A Lichtenberg, Alexandru Iordan, Jessica Mozersky, Benjamin M Hampstead","doi":"10.1177/25424823261429997","DOIUrl":"10.1177/25424823261429997","url":null,"abstract":"<p><strong>Background: </strong>There is strong desire for the return of individual results, including biomarker testing, among participants in Alzheimer's disease and related dementias (ADRD) studies. However, it is not known whether participants accurately understand the utility, limitations, benefits and risks of biomarker disclosure, nor how they weigh these factors to inform their decision to undergo testing and learn results. Furthermore, little is known about how factors like participant race or diagnosis influence a desire to learn biomarker results.</p><p><strong>Objective: </strong>This mixed-methods study explored how clinically and racially diverse participant-care partner dyads perceive and plan to use AD biomarker testing in the context of research studies.</p><p><strong>Methods: </strong>57 participants (Age: <i>M</i> = 74.28 ± 5.98; Race: <i>n</i> = 22 Black, <i>n</i> = 35 White; Diagnosis: <i>n</i> = 23 with mild cognitive impairment; <i>n</i> = 34 cognitively healthy) and care partners were recruited from AD studies wherein the participant completed amyloid-<i>β</i> and tau positron emission tomography without receiving results. Each completed an independent interview about their perspectives on learning the participant's results.</p><p><strong>Results: </strong>Responses suggested strong interest in learning results, driven by perceived benefits (e.g., informing treatment, lifestyle changes, and social support). Risks were rarely discussed, though some respondents cited concerns about psychological burdens of a positive result. Few nuanced differences in perceived risks or benefits were observed across race and diagnosis.</p><p><strong>Conclusions: </strong>The decision to learn the results of biomarker testing is motivated by highly varied perceived benefits and minimal consideration of risks. Testing should be preceded by individualized counseling that carefully reviews potential benefits and risks.</p>","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"10 ","pages":"25424823261429997"},"PeriodicalIF":2.8,"publicationDate":"2026-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13039044/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147610729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic association of ante-mortem biomarkers with cerebral amyloid angiopathy in a cohort with high Alzheimer's disease comorbidity.","authors":"Kemi Hou, Haojun Lu, Rong Zhang, Yadong Wang, Ge Xu, Fengdan Long, Juan Lu, Dong Xing, Lingling Huang, Yaming Sun","doi":"10.1177/25424823261433955","DOIUrl":"10.1177/25424823261433955","url":null,"abstract":"<p><strong>Background: </strong>Cerebral amyloid angiopathy (CAA) frequently co-occurs with Alzheimer's disease (AD), complicating the interpretation of biomarkers. Current diagnostic approaches rely largely on neuroimaging but remain constrained by limited accuracy.</p><p><strong>Objective: </strong>This study aimed to evaluate the diagnostic discrimination and pathological association of neuropathological scoring systems and fluid biomarkers for CAA using pathologically confirmed samples.</p><p><strong>Methods: </strong>We examined 100 participants from the Alzheimer's Disease Neuroimaging Initiative with complete neuropathological assessments. Associations and diagnostic performance of amyloid-β (Aβ)-related measures were evaluated using multivariable regression and receiver operating characteristic analyses.</p><p><strong>Results: </strong>Both Thal phase and the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) score were associated with CAA status. Cerebrospinal fluid (CSF) Aβ₄₂, Aβ₄₀, and Aβ₃₈ concentrations were significantly reduced in CAA, with CSF Aβ₄₂ showing the greatest decrease and highest diagnostic accuracy [area under the curve (AUC) 0.962; sensitivity 88.6%; specificity 100%). Plasma Aβ_42/40 ratio was also markedly lower in CAA and demonstrated robust diagnostic discrimination (AUC 0.913; sensitivity 84.6%; specificity 100%). In contrast, inflammatory and neuronal injury markers did not differ significantly between groups.</p><p><strong>Conclusions: </strong>Neuropathological scores and fluid biomarkers are associated with the presence and severity of CAA, but this association is confounded by co-existing advanced AD pathology. Despite high discriminative accuracy, the small control sample warrants cautious interpretation of specificity estimates.</p>","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"10 ","pages":"25424823261433955"},"PeriodicalIF":2.8,"publicationDate":"2026-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13039034/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147610551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of novel serum biomarkers for Alzheimer's disease screened by phage display library of random peptides.","authors":"Dandan Gao, Zhicheng Han, Xiaoyang Ai, Fengyu Wang, Danyun Lai, Chenhao Gao, Zhaohui Zhang, Shengce Tao, Junkui Shang, Jiewen Zhang","doi":"10.1177/25424823261432141","DOIUrl":"10.1177/25424823261432141","url":null,"abstract":"<p><strong>Background: </strong>Identification of Alzheimer's disease (AD) needs inexpensive, noninvasive novel biomarkers. autoimmunity plays a key role in the pathogenesis of AD.</p><p><strong>Objective: </strong>This study aims to screen innovative diagnostic biomarkers for AD from the perspective of autoantibodies.</p><p><strong>Methods: </strong>The study consisted of two screening phases and two validation phases. AD serum autoantibody-related biomarkers were discovered and validated using serum samples from four independent cohorts encompassing 241 participants, i.e., AD patients, healthy controls, and other dementia-related diseases. First, to identify biomarkers for AD, a phage displayed random peptide library (Ph.D.12) was applied to screen specific autoantibodies in a total of 71 serum samples from 39 AD patients and 32 healthy controls. After further screening by polypeptide microarray, Then, for validation, three peptides were analyzed in another two independent cohorts, which included AD patients, healthy controls, and other dementia-related diseases, Enzyme-linked immunosorbent assay (ELISA) was finally used to evaluate their sensitivity and specificity for AD diagnosis.</p><p><strong>Results: </strong>Our results show that both AD2024Val03, AD2024Val70, and AD2024Val72 showed a statistically significant ability to discriminate AD patients from controls and other dementia-related diseases. Additionally, combination of these three peptides, AD2024Val, could greatly improve the diagnostic performance (AUC is above 0.95, sensitivity ∼100%, specificity ∼79%).</p><p><strong>Conclusions: </strong>the peptides we identified could serve as promising blood biomarkers for AD clinical diagnosis, which also might provide new insights into the potential pathogenesis of AD.</p>","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"10 ","pages":"25424823261432141"},"PeriodicalIF":2.8,"publicationDate":"2026-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13039055/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147610593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenges in community-based recruitment of Alzheimer's disease cases: Experience of the monitoring drug efficacy through multi-omics research initiative in Alzheimer's disease (MEMORI-AD) study.","authors":"Fresthel Monica M Climacosa, Eric David B Ornos, Erwin Rommel S Diwa, Mary Gale R Guantia, Almeera P Qureshi, Nicole Clarence Louise L Gapaz, Aira B Dacasin, Joannes Luke B Asis, Ajina C Carampel, Angelica M Dela Cruz, Francis James A Gordovez, John Carlo B Reyes, Ian Kim B Tabios, Rafael Vincent M Manalo, Joana Marie C Cruz, Veeda Michelle M Anlacan","doi":"10.1177/25424823261431318","DOIUrl":"10.1177/25424823261431318","url":null,"abstract":"<p><strong>Background: </strong>The Monitoring drug Efficacy through Multi-Omics Research Initiative in Alzheimer's Disease (MEMORI-AD) study aims to characterize drug response to donepezil and memantine in a Filipino cohort with late-onset Alzheimer's disease (AD). To enhance enrollment, community-based dementia screening and recruitment were conducted across barangays in Manila.</p><p><strong>Objective: </strong>This study describes the experiences and challenges in community-based recruitment for multi-omics research in vulnerable populations.</p><p><strong>Methods: </strong>After coordinating with local officials for approval, recruitment targeted residents aged 65 years and above. A public health lecture on dementia was held, followed by rapid screening using the \"10 Warning Signs of Dementia\" questionnaire by the Alzheimer's Disease Association of the Philippines and the AD-8 Dementia Screening Interview. Eligible participants were invited for clinical screening, including laboratory work, neuropsychological tests, and neuroimaging. Reasons for non-consent and withdrawal were recorded.</p><p><strong>Results: </strong>Of 301 eligible participants, 42 (14.0%) were suspected of dementia and eligible for work-up. Among them, 14 (33.3%) did not consent, 15 (53.6%) initially consented but withdrew, and 13 (46.4%) completed the assessment. Only 2 patients were enrolled. The main cause for non-consent was disinterest (n = 8, 57.1%), followed by unavailability of a legally authorized representative (LAR) (n = 3, 21.4%), which was also the primary reason for withdrawal (n = 9, 60%).​.</p><p><strong>Conclusions: </strong>Recruitment of vulnerable Filipinos in multi-omics research within a lower-middle income country faced significant barriers, encompassing economic, psychosocial, and health constraints, largely due to disinterest and unavailability of LAR. Further studies on family dynamics, socioeconomic, and cultural factors could offer insights to overcome these recruitment barriers.</p><p><strong>Trial registration number: </strong>Philippine Health Research Registry ID PHRR230220-0054116; ClinicalTrials.gov ID NCT05801380.</p>","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"10 ","pages":"25424823261431318"},"PeriodicalIF":2.8,"publicationDate":"2026-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13039053/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147610871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}